This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.
The total number entries retrieved from this search are 315Biomarker ID | Biomarker | Biomolecule | Subject | Regulation | Biomarker's type | Experiment | Level of significance | Source | PMID |
---|---|---|---|---|---|---|---|---|---|
2180 | circCDK13 | circRNAs | Human | Suppressed expression in liver cancer | Diagnostic | Normal cell line vs cancer cell line | p < 0.05 | Tissue | 29658568 |
2199 | MTHFR | RNAs | Human | MTHFR polymorphism was associated with HCC occurrence | Prognostic | Normal vs HCC; predict recurrence in patients | p < 0.05 | Tissue | 29185200 |
2246 | HLA-C | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 67 fold change) | Diagnostic | HCC and CHC v/s normal | p < 0.01 | Tissue | 11401510 |
2247 | B2M | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 67 fold change) | Diagnostic | HCC and CHC v/s normal | p < 0.01 | Tissue | 11401510 |
2248 | BR1 | RNAs | Human | Upregulated in HCC and CHC v/s normal (with 19 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2249 | GPC3 | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 15 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2250 | UBD | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 12 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2251 | CXCL10 | RNAs | Human | Upregulated in HCC than CHC and normal (with nearly 13 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2252 | CYP3A4 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 42 and 50 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2253 | CYP4A11 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 17 and 30 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2254 | SLC22A1 | RNAs | Human | Downregulated in HCC than CHC and normal (with nearly 8 and 17 fold change) | Diagnostic | HCC v/s CHC and normal | p < 0.01 | Tissue | 11401510 |
2260 | CDK4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2261 | Bax | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2262 | NOTCH4 | RNAs | Human | Upregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2263 | ISGF3G | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2264 | TNF | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2265 | VISA | RNAs | Human | Downregulated | Diagnostic and prognostic | HCC with Cirrhosis v/s HCC without Cirrhosis | p < 0.05 | Tissue | 18959789 |
2266 | AURKB-Sv2 variant | RNAs | Human | Upregulated in metastatic HCC than primary HCC and Absent in normal | Prognostic | Metastatic HCC v/s Primary HCC; correlated with a poor outcome and short disease-free period | p < 0.01 | Cell line and Tissue | 19134008 |
2267 | SPP1 | RNAs and Protein | Human | Upregulated in PT than PN (with 3 fold change) | Diagnostic | Metastatic HCC v/s Primary HCC | p < 0.01 | Tissue | 12640447 |
2268 | LIMK1, CENPE, FZD2, ENO2, ITGA9, COPA, KIAA0660, GTF2H1, VPS41, RGS20, MATK, STOML1, BASP1, EPB42, ALDH3B2, MEL, CAT56, RAB3A, PSCD3, PLD2, ADCYAP1R1, ALDH3B1, RHD, CSF3R, KIAA0063, KIAA0296, LRP6, ENO3, CTRB1, YES1, IncytePD:1404153, GYS1, MDFI, GABRE, IncytePD:2685601, CD3Z, DTYMK, SPTBN2, IncyteP | RNAs | Human | Upregulated in PT than PN (with 3 fold change) | Diagnostic | Metastatic HCC v/s Primary HCC | p < 0.01 | Tissue | 12640447 |
2292 | RPS5 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 6.35) and (v/s HCV associated HCC with ratio of 2.38) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2293 | KRT8 | RNAs | Human | Upregulated in HBV associated HCC ( v/s normal with fold change 5.68) and (v/s HCV associated HCC with ratio 3.19) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2294 | CFLAR | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 2.86) and (v/s HCV associated HCC with ratio of 2.09) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2295 | ATP5F1 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 4.19) and (v/s HCV associated HCC with ratio of 3.52) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2296 | IGFBP2 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 3.37) and (v/s HCV associated HCC with ratio of 2.49) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2297 | MAP3K5 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 3.76) and (v/s HCV associated HCC with ratio of 2.33) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2298 | MMP9 | RNAs | Human | Upregulated in HBV associated HCC (v/s normal samples with fold change 7.43) and (v/s HCV associated HCC with ratio of 3.74) | Diagnostic | HBV associated HCC v/s normal and HCV associated HCC | p < 0.05 | Tissue | 18932288 |
2299 | VIM | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 8.61) and (ratio of HBV-HCC v/s HCV-HCC 0.28) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2300 | ACTB | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 4.13) and (ratio of HBV-HCC v/s HCV-HCC 0.37) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2301 | GAPD | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 5.27) and (ratio of HBV-HCC v/s HCV-HCC 0.29) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2302 | CD58 | RNAs | Human | Upregulated in HCV associated HCC (v/s normal samples with fold change 4.68) and (ratio of HBV-HCC v/s HCV-HCC 0.31) | Diagnostic | HCV associated HCC v/s normal and HBV associated HCC | p < 0.05 | Tissue | 18932288 |
2303 | CD24 | RNAs | Human | Upregulated in the high-risk group | Prognostic | Early recurrence of HCC v/s Late recurrence of HCC | p < 0.001 | Tissue | 18381945 |
2304 | CLDN10 | RNAs | Human | Upregulated in Cirrhosis v/s control and early and advanced HCC | Diagnostic | Cirrhosis v/s Low/High grade dysplastic nodules, normal and early/Late HCC | p < 0.05 | Tissue | 17393520 |
2305 | GREM2 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2306 | EPO | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2307 | NRG1 | RNAs | Human | Upregulated in dysplasia v/s control and early/advanced HCC | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2308 | ASPM | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2309 | PRIM1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2310 | HMMR | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2311 | IRAK1 | RNAs | Human | Upregulated in early/advanced HCC v/s control and dysplasia | Diagnostic | dysplasia v/s early/late HCC and normal | p < 0.05 | Tissue | 17393520 |
2312 | C/EBP | RNAs | Human | Downregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2313 | HNF-1 | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2314 | HNF-3beta | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2315 | HNF-4alpha | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2316 | HNF-4gamma | RNAs | Human | Upregulated in cancer | Diagnostic | HCC v/s non-tumor HCC | NA | Tissue | 11306505 |
2317 | NDRG2 | Protein and RNAs | Human | Downregulated in HCC than non-tumor | Diagnostic and Prognostic | HCC v/s cirrhosis/healthy/non-tumor HCC; associated with recurrence and tumor grade | p < 0.05 | Tissue | 18519680 |
2318 | CSTB | Protein and RNAs | Human | Upegulated in HCC than non-tumor | Diagnostic | HCC v/s cirrhosis/healthy/non-tumor HCC | p < 0.05 | Serum | 18281540 |
2321 | TGF beta | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
2322 | Myc | RNAs | Human | Upegulated in HCC than non-tumor | Prognostic | early occurrence v/s late recurrence | NA | Tissue | 20380719 |
2323 | LOC388796, A_32_P406142, SAFB, MKL1, TNKS1BP1, PMM2, PPP2R5C, SAFB2, GATA4, RASD1, KIAA1967, | RNAs | Human | over expressed in subjects with fastest recurrence | Prognostic | early occurrence v/s late recurrence | p < 0.0001 | Tissue | 20380719 |